IRF-7 Antibody, anti-human, REAfinity™
Synonyms: IRF7, IMD39, IRF-7H, IRF7A, IRF7B, IRF7C
RECOMBINANT EXTENDED VALIDATION
Clone:
REA521 | K40-321
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for IRF-7 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
FITC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-108-906, 130-108-876
Description:
HEK-EBNA cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-IRF-7 antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:11
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-108-906, 130-108-876
Testing grade:
Extended validation for IRF-7 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA310
K47-671
high
REA521
low

Cells were incubated with an excess of purified unconjugated IRF-7 (REA521) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for IRF-7 Antibody, anti-human, REAfinity™
Overview

Clone REA521 recognizes the human interferon regulatory factor 7 (IRF-7) antigen, regardless of phosphorylation status. IRF-7 is a member of the IRF family of transcription factors and a key player in the innate immune response against viral infections. Constitutive expression of IRF-7 is limited to peripheral blood lymphocytes and dendritic cells while in most cell types its expression can be induced by type I interferon. IRF-7 is sequestered in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA, or toll-like receptor signaling, it becomes phosphorylated by TBK and IKK-i kinases. Phosphorylated IRF-7 migrates in the nucleus where it can activate interferon type I genes and other interferon-stimulated genes.

Additional information: Clone REA521 displays negligible binding to Fc receptors.

Alternative names

IRF7, IMD39, IRF-7H, IRF7A, IRF7B, IRF7C

Detailed product information

Technical specifications

Clone
REA521
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
IRF-7
Molecular mass of antigen [kDa]
54
Distribution of antigen
dendritic cells, lymphocytes
Entrez Gene ID
RRID
AB_2652525, AB_2652524, AB_2905298, AB_2905297, AB_2652522, AB_2652523

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for IRF-7 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for IRF-7 Antibody, anti-human, REAfinity™
Publications
  1. Smith, E. J. et al. (2001) IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J. Biol. Chem. 276 (12): 8951-8957
  2. Sgarbanti, M. et al. (2007) IRF-7: new role in the regulation of genes involved in adaptive immunity. Ann. N. Y. Acad. Sci. 1095: 325-333
  3. Zhang, L. and Pagano, J. S. et al. (1997) IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol. Cell. Biol. 17 (10): 5748-5757

You have previously chosen International as your location.
What do you want to do?